Q3 Earnings Forecast for QuidelOrtho Issued By William Blair

Key Points

• QuidelOrtho Corporation is expected to post earnings of $0.78 per share for Q3 2025, with a full-year earnings consensus estimate of $2.30 per share.
• Analyst ratings for QuidelOrtho are mixed, with one sell rating, three hold ratings, and four buy ratings, leading to an average rating of "Hold" and a target price of $42.17.
• The company's stock recently opened at $24.40 and has experienced a 4.1% increase, with a market capitalization of $1.65 billion.

QuidelOrtho Corporation (NASDAQ:QDEL - Free Report) - Equities research analysts at William Blair issued their Q3 2025 earnings per share estimates for QuidelOrtho in a research note issued to investors on Wednesday, August 6th. William Blair analyst A. Brackmann forecasts that the company will earn $0.78 per share for the quarter. The consensus estimate for QuidelOrtho's current full-year earnings is $2.30 per share. William Blair also issued estimates for QuidelOrtho's Q4 2025 earnings at $0.76 EPS, FY2025 earnings at $2.27 EPS, Q1 2026 earnings at $0.78 EPS, Q2 2026 earnings at $0.26 EPS, Q3 2026 earnings at $0.94 EPS, Q4 2026 earnings at $0.97 EPS and FY2026 earnings at $2.95 EPS.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.01 by $0.11. The company had revenue of $613.90 million for the quarter, compared to the consensus estimate of $612.36 million. QuidelOrtho had a positive return on equity of 5.29% and a negative net margin of 16.10%. QuidelOrtho's revenue for the quarter was down 3.6% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.07) earnings per share.

QDEL has been the topic of a number of other research reports. UBS Group lowered their price target on QuidelOrtho from $29.00 to $26.00 and set a "neutral" rating on the stock in a research report on Thursday, August 7th. Citigroup decreased their target price on QuidelOrtho from $50.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, August 6th. Jefferies Financial Group upgraded QuidelOrtho from a "hold" rating to a "buy" rating and set a $44.00 target price on the stock in a research report on Thursday, May 8th. Wall Street Zen downgraded QuidelOrtho from a "buy" rating to a "hold" rating in a research report on Saturday, July 26th. Finally, JPMorgan Chase & Co. decreased their target price on QuidelOrtho from $38.00 to $25.00 and set an "underweight" rating on the stock in a research report on Monday, April 21st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $42.17.

QuidelOrtho Price Performance

QDEL stock traded up $1.39 during mid-day trading on Friday, reaching $25.03. 550,471 shares of the company's stock were exchanged, compared to its average volume of 1,326,894. The company has a market cap of $1.70 billion, a price-to-earnings ratio of -3.83 and a beta of -0.04. The stock's 50 day moving average is $27.81 and its 200 day moving average is $32.18. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.12 and a quick ratio of 0.62. QuidelOrtho has a 12-month low of $22.05 and a 12-month high of $49.45.

Institutional Investors Weigh In On QuidelOrtho

Hedge funds and other institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC increased its stake in QuidelOrtho by 230.3% during the first quarter. AQR Capital Management LLC now owns 2,655,576 shares of the company's stock worth $90,130,000 after acquiring an additional 1,851,590 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its stake in QuidelOrtho by 19.6% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 11,238,826 shares of the company's stock worth $500,690,000 after acquiring an additional 1,840,667 shares during the last quarter. Invesco Ltd. increased its stake in QuidelOrtho by 71.7% during the fourth quarter. Invesco Ltd. now owns 3,447,446 shares of the company's stock worth $153,584,000 after acquiring an additional 1,439,293 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in QuidelOrtho by 201.6% during the second quarter. Assenagon Asset Management S.A. now owns 941,370 shares of the company's stock worth $27,130,000 after acquiring an additional 629,246 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in QuidelOrtho by 46.1% during the second quarter. Geode Capital Management LLC now owns 1,678,670 shares of the company's stock worth $48,385,000 after acquiring an additional 529,770 shares during the last quarter. Institutional investors and hedge funds own 99.00% of the company's stock.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.